Company Filing History:
Years Active: 2024
Title: Mary Elizabeth Dooley: Innovator in Cancer Diagnostics
Introduction
Mary Elizabeth Dooley is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer diagnostics, particularly in the development of companion diagnostics for CDK4 inhibitors. Her work is vital in evaluating the effectiveness of cancer treatments.
Latest Patents
Mary Elizabeth Dooley holds a patent for "Enigma and CDH18 as companion diagnostics for CDK4 inhibitors." This patent relates to the use of specific biomarkers to assess the likelihood that a CDK4 inhibitor will produce an anti-cancer effect in a patient. The disclosure provides methods, compositions, and kits for a companion diagnostic, focusing on the colocalization of Enigma and CDH18 biomarkers within cancer foci to determine the potential success of CDK4 inhibition in treatment.
Career Highlights
Mary is affiliated with the Memorial Sloan Kettering Cancer Center, where she applies her expertise in cancer research and diagnostics. Her innovative approach has positioned her as a key figure in the development of new therapeutic strategies.
Collaborations
Mary collaborates with esteemed colleagues, including Marta Kovatcheva and Samuel Singer, to advance research in cancer diagnostics and treatment.
Conclusion
Mary Elizabeth Dooley's contributions to cancer diagnostics through her innovative patent highlight her role as a leading inventor in the field. Her work continues to impact the effectiveness of cancer treatments and improve patient outcomes.